The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2

Арутюнов, Г. П.; Тарловская, Е. И.; Козиолова, Н. А.; Болдина, М. В.; Батюшин, М. М.; Аметов, А.С.; Арутюнов, А. Г.; Белевский, А. С.; Галстян, Г. Р.; Григорьева, Н. Ю.; Джунусбекова, Г А; Есаян, А. М.; Malchikova, S. V.; Митьковская, Н. П.; Мкртумян, А. М.; Орлова, Я.А.; Петрова, М. М.; Ребров, А. П.; Рузанов, Д. Ю.; Салухов, В. В.; Sisakian, A S; Скибицкий, В. В.; Sugraliyev, Akhmetzhan; Фомин, И. В.; Халимов, Ю. Ш.; Чесникова, А. И.; Шапошник, И. И.; Шестакова, М. В.

doi:10.26442/00403660.2020.09.000703

Cited by 8 publications

(1 citation statement)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Коморбидная сердечно-сосудистая патология является негативным фактором течения и прогноза COVID-19 и увеличивает риск госпитализации и смерти в 6 и 12 раз соответственно; 80% пациентов с коморбидностью переносят инфекцию в тяжелой форме [2,3]. Многочисленные клинические исследования демонстрируют тесную связь между наличием сопутствующих ССЗ и традиционных кардиоваскулярных факторов риска (пожилой возраст, артериальная гипертензия (АГ), ожирение «Рецепт», 2022, том 25, № 4 и сахарный диабет (СД)) и тяжелым течением COVID-19 и высокой внутрибольничной летальностью [4].…”

Section: коморбидная сердечно-сосудистая патология и Covid-19unclassified

Statins and COVID-19: Review of Recommendations and Clinical Practice

Патеюк¹

2022

Рецепт

View full text Add to dashboard Cite

According to the latest international clinical guidelines, statins remain the main group of drugs effective for the treatment of dyslipidemia and the prevention of cardiovascular disease (CVD) and complications. The article discusses the links of pathogenesis and mechanisms of damage to the cardiovascular system, analyzes the relationship with comorbidity, substantiates the need to search for effective and affordable therapeutic agents in the treatment of COVID-19. Statins have mechanisms of action that can affect the penetration of the virus into human cells, have an anti-inflammatory effect, improve the functional state of the vascular endothelium and reduce the risk of complications. The effectiveness of statins in patients with COVID-19 and high cardiovascular risk suggests that they need to be continued. In real clinical practice, priority should be given to effective and safe statins. Rosuvastatin is highly effective and safe, including a low risk of drug-drug interactions, and is the optimal therapeutic agent at all stages of cardiovascular prophylaxis.

show abstract

Section: коморбидная сердечно-сосудистая патология и Covid-19unclassified

Statins and COVID-19: Review of Recommendations and Clinical Practice

Патеюк¹

2022

Рецепт

View full text Add to dashboard Cite

show abstract

Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology

Arutyunov

Seferović²,

Бакулин

et al. 2021

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

By the middle of 2021, the official global number of coronavirus disease 2019 (COVID-19) patients was close to 230 million, but the number accounting for asymptomatic patients was much higher. Consequences and rehabilitation after COVID-19 are of particular interest and raise many controversial and unresolved issues. On May 18, 2021, the Eurasian Association of Therapists organized an international panel of experts to analyze challenges associated with the post-COVID-19 period. This panel aimed to develop approaches to identify gaps in the discussed issues. This interdisciplinary team of leading experts reviewed the current literature and presented their data to formulate practical guidance on management of patients after COVID-19. The panel of experts also presented recommendations on how to implement the gained knowledge into health care practices.

show abstract

Place of renin-angiotensin-aldosterone system inhibitors and statins in the treatment of cardiovascular patients in the context of COVID-19 pandemic

Sayutina

Butorova

Туаева

et al. 2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Patients at high cardiovascular risk, older people with cardiovascular comorbidities, as well as those with hypertension and familial hypercholesterolemia are more susceptible to severe coronavirus disease 2019 (COVID-19). Such patients are likely to be at increased long-term atherothrombotic risk after COVID-19. The renin-angiotensinaldosterone system (RAAS) not only plays a key role in the development and progression of cardiovascular diseases, but is also responsible for the penetration of the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) into the cells of target organs and the development of infection. Given that RAAS inhibitors and statins increase the expression of angiotensin-converting enzyme type 2 receptors, concerns were initially raised about their possible adverse effect on COVID-19 course. However, at present, we have data from large-scale, including randomized clinical trials and meta-analyses, confirming the organ protective effects of RAAS inhibitors and statins by reducing the inflammation severity and fibrosis in tissues. The review attempted to assess the potential role of these drugs in the management of SARS-CoV-2-infected patients and their impact on the development of complications.

show abstract

The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2

Cited by 8 publications

References 74 publications

Statins and COVID-19: Review of Recommendations and Clinical Practice

Statins and COVID-19: Review of Recommendations and Clinical Practice

Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology

Place of renin-angiotensin-aldosterone system inhibitors and statins in the treatment of cardiovascular patients in the context of COVID-19 pandemic

Contact Info

Product

Resources

About